53. Sjogren syndrome Clinical trials / Disease details

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01693393 (ClinicalTrials.gov)	March 2010	14/9/2012	Low Dose Cyclosporin A in Primary Sjögren Syndrome	A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren Syndrome	Sjögren´s Syndrome	Drug: Cyclosporine A	Charite University, Berlin, Germany	NULL	Completed	18 Years	75 Years	Both	30	Phase 2	Germany
2	EUCTR2009-013976-38-DE (EUCTR)		07/12/2009	Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - Cypress	Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - Cypress	Primary Sjögren's Syndrome MedDRA version: 12.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome	Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral INN or Proposed INN: CICLOSPORIN Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral INN or Proposed INN: CICLOSPORIN Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral INN or Proposed INN: CICLOSPORIN	Charité Berlin, Department of rheumatology	Charité Berlin, department of rheumatology;Charité Berlin, department of rheumatology	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Germany